Scientists find a ‘kill switch’ in the body that can destroy cancer cells

Each advancement in cancer research brings renewed hope to millions battling this devastating disease.

Scientists at the UC Davis Comprehensive Cancer Center in Sacramento, California, have introduced a promising new approach to cancer treatment. Their findings, published in the journal Cell Death & Differentiation, highlight a breakthrough in targeting cancer cells.

Their research focuses on CD95 receptors, also known as Fas or “death receptors,” which trigger cancer cells to self-destruct. “Previous attempts to target this receptor have failed. However, now that we’ve identified this epitope (target), we may have a viable therapeutic strategy for addressing Fas in tumors,” explained Jogender Tushir-Singh, senior author of the study and associate professor in the Department of Medical Microbiology and Immunology.

These CD95 receptors are found on the surface of cells and, when activated, initiate molecular processes leading to cell destruction. While they are crucial for maintaining cellular balance, their full potential has remained largely unexplored until now.

One of the greatest challenges in cancer treatment is therapeutic resistance, where cancer cells adapt and become unresponsive to conventional therapies. Currently, standard treatments include surgery, chemotherapy, and radiotherapy. Additionally, immune-based therapies such as CAR (chimeric antigen receptor) T-cell therapy have been introduced, but their success has been limited to specific cancer types.

“Although CAR T-cell therapies have shown promise in treating blood cancers like leukemia, achieving long-term remission remains a major hurdle,” Tushir-Singh told Fox News.

The study suggests that this new discovery could significantly improve the effectiveness of CAR-T therapies, expanding their potential beyond leukemia to solid tumors.

By targeting the Fas epitope, researchers hope to prevent cancer cells from evading treatment by inducing programmed cell death. This approach could not only help overcome therapeutic resistance but also enhance the effectiveness of existing immunotherapies.

“The success of CAR-T therapy depends on off-target killing through Fas,” Tushir-Singh told Fox News Digital. He further emphasized the importance of screening cancer patients for Fas expression before undergoing CAR-T therapy to determine its potential effectiveness.

Related Posts

Nicole Kidman posing half-nak*d

Kidman posing half-naked with her legs spread wide is something married men shouldn’t see! No wonder even Cruise was madly in love with her! One of the…

Walmart Shoppers: Must-Know Tips for Your Next Visit

For decades, Walmart has been a cornerstone of American retail, known for affordability, variety, and convenience. In recent years, self-checkout lanes became a central part of the…

DEADLY FALL Prince Harry is devastated with grief.

A shocking loss has hit Prince Harry as the 98-year-old 8th Marquess of Ailesbury, Michael Brudenell-Bruce, fell from his bedroom window while freeing his stuck cat, Honeybun.Discovered…

Doctor notices something unusual about David Beckham – issues serious health alert

David Beckham, a global icon both on and off the football field, has long been admired not only for his athletic achievements but also for his polished…

Girl was hospitalized

Last night, I used my girlfriend’s phone and saw an open article titled “Blowjob tips for small penises.” I laughed it off at first, thinking it was…

These are the consequences of sleeping with…See more

Sleeping with the wrong person can lead to emotional turmoil that lingers long after the physical encounter is over. When intimacy is shared with someone who doesn’t…